Trial Profile

A Phase 1/2, Multicenter, Open-label Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IBI 354 (Primary)
Indications Advanced breast cancer; Biliary cancer; Colorectal cancer; Gastric cancer; HER2 positive breast cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Innovent Biologics

02 Jun 2025 According to Innovent Biologics media release, data from this trial was presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
02 Jun 2025 Results presented in the Innovent Biologics media release.
23 Apr 2025 According to Innovent Biologics media release, a poster presentation of the data from this study will be delivered at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 from May 30 to June 3, 2024, in Chicago, Illinois, U.S.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com